Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “SHOCK THERAPY”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed1975

Shock therapy and psychiatric malpractice: the legal accommodation to a controversial treatment.

Shock therapy has developed over the years into an accepted form.of psychiatric treatment for relieving the symptoms of certain mental illnesses. The development of shock therapy did and still does take place in a legal environment which leaves the reasonable psychiatrist free to experiment. The discovery of muscle-relaxing drugs and their introduction into the treatment procedure were undoubtedly encouraged by the possibility of malpractice suits arising from bone fracture caused by rapidly contracting muscles. Today the incidence of malpractie suits involving shock therapy has been reduced, and a reasonable psychiatrist exercising care remains free to treat without concern over the possibility of a successful malpractice action.

Convulsive Therapy↗
PubMed2003

Can we predict which patients with implantable cardioverter defibrillators receive appropriate shock therapy? A study of 155 patients.

BACKGROUND: Appropriate shock therapy (AST) occurs in the minority of patients with implantable cardioverter defibrillators (ICDs). We assessed which patients received AST and whether there were any predictive factors. METHODS: We retrospectively analysed data from 155 patients implanted with ICDs at our institution from a period from February 1984 to February 2001. Stored electrogram data were analysed. We sub-divided patients on the basis of underlying cardiac disease. Various clinical echocardiographic and electrophysiological variables were studied. RESULTS: AST occurred in 53 (34%) of patients (Group 1) and no AST in 102 (64%) of patients (Group 2). Impaired LV function was significantly associated with AST. Group 1 patients had a lower ejection fraction (EF) compared to Group 2 (37.5+/-13% vs. 47.8+/-14%, P<0.0001). Seventy-two percent of patients with AST had an EF <40% vs. 35% of patients in Group 2 (P<0.0001). NYHA Class was also associated with AST, 42% of Group 1 were in NYHA Class III/IV vs. 12% in Group 2 (P<0.001). Programmed electrical stimulation (PES) was a predictor of AST. PES was positive in a greater proportion of patients in Group 1 vs. 2 (88% vs. 64%, P<0.0006). Sub-group analysis showed that patients with dilated cardiomyopathy (DCM) had a high incidence of AST (80%). In these patients PES was a poor predictor of AST being positive in only 25%. CONCLUSION: AST occurs in the minority of our patients. Certain pre-procedural variables predict AST. PES does not appear useful in predicting shock therapy in DCM patients and a negative PES should not preclude ICD implantation in this group.

Adult↗
PubMed1991

Value of ventricular electrogram recordings in the diagnosis of arrhythmias precipitating electrical device shock therapy.

An antitachycardia pacemaker-cardioverter-defibrillator that is capable of storing ventricular electrograms before and after delivery of device shock therapy was implanted in 16 patients. Three of the patients experienced out-of-hospital device shock therapy preceded by minimal symptoms. Although limitations of electrogram analysis exist and are discussed, careful analysis and registration of electrograms during all supraventricular and ventricular rhythms observed during in-hospital testing served as an important reference for subsequent arrhythmia diagnosis. By analyzing the electrogram rate and RR interval stability and configuration, a definitive diagnosis was established in all three patients (atrial fibrillation, polymorphic ventricular tachycardia and rate-sensing lead disruption, respectively). Thus, the ability to store ventricular electrograms before shock therapy represents a major advance in the management of patients who receive an electrical device to treat ventricular tachyarrhythmia.

Adult↗
PubMed1988

Evaluation of the role of pre- and postsynaptic serotonergic receptors in electroconvulsive shock therapy.

Despite the well-established clinical efficacy of electroconvulsive therapy (ECT) in the treatment of affective disorders, there is no generally accepted theory regarding its mode of action. Pre- and postsynaptic serotonin (5-hydroxytryptamine, 5-HT) receptors were studied following treatment of rabbits with electroconvulsive therapy (8 shocks). No change was observed in the binding at the postsynaptic 5-HT2 receptor in frontoparietal cortex, as indicated by an unchanged affinity and by the total number of receptors. In control rabbits, exogenously added serotonin and metitepin modulated the electrically evoked 3H-serotonin release, probably by acting on a presynaptic serotonin autoreceptor. Following electroconvulsive therapy, exogenous serotonin still inhibited the 3H-serotonin release, whereas metitepin had lost its enhancing effect. This observation provides evidence for a decreased amount of endogenous neurotransmitter present in the synaptic cleft at stimulation. The results indicate that postsynaptic receptor changes following antidepressant treatments are related to the presynaptic autoreceptor changes.

Animals↗
PubMed1998

Cardiogenic shock: therapy and prevention.

Cardiogenic shock is defined as profound circulatory failure resulting in insufficient tissue perfusion to meet resting metabolic demands. It occurs in approximately 7.5% of patients with acute myocardial infarction. Treatment strategies include inotropic agents, use of intra-aortic balloon counterpulsation, and revascularization. Current evidence supports the use of primary angioplasty. Surgery should be considered in patients with triple-vessel disease. If early catheterization is not available, thrombolytic therapy should be given to eligible patients and transfer to an interventional facility should be considered. Effective therapy for shock must also include a prevention strategy. This requires identification of patients at high risk for shock development and selection of patients who are candidates for aggressive intervention.

Cardiotonic Agents↗
PubMed1957

[Shock therapies].

Explore the source record for details and available documents.

Convulsive Therapy↗
PubMed2006

Withdrawing implantable defibrillator shock therapy in terminally ill patients.

PURPOSE: The purpose of this study is to review a multidisciplinary strategy used to identify patients with terminal illnesses and initiate withdrawal of implantable cardioverter defibrillator (ICD) shock therapy as part of a comprehensive comfort care approach. With indications for ICDs increasing, more patients are receiving devices. Once protected from an arrhythmic death, these patients may develop other terminal diseases such as cancer or congestive heart failure. It is appropriate to withdraw defibrillator shock therapy when such patients desire only comfort care. METHODS: The charts of ICD patients who had died were reviewed. Two groups emerged: Group 1 (20) included patients whose defibrillator was turned off through the comprehensive comfort care approach. Group 2 (43) included patients whose clinical course was so rapid that the defibrillator was not turned off. Pacing therapy was not withdrawn in either group. RESULTS: Defibrillator discharges, cause of death, and time from ICD discharge to death were compared. Group 2 patients died more acutely than Group 1. Group 1 experienced fewer shocks prior to death when compared to Group 2. Comparing pacemaker dependent and non-dependent patients, there was no difference in the time between therapy discontinuation and death. CONCLUSION: This is the largest study to date to review the characteristics of patients with ICDs and terminal illness. Only one-third of terminally ill patients with ICDs were able to have shock therapy withdrawn as part of a comfort care strategy. These patients experienced fewer shocks in the final days of their illness.

Aged↗
PubMed2003

Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life.

BACKGROUND: This study used a device (DDD implantable cardioverter defibrillator [ICD]) capable of delivering pacing and shock therapies to restore normal sinus rhythm in patients with atrial tachycardias or atrial fibrillation (AF). The purpose of this study was to assess the effect of the device on patient-perceived, health-related quality of life (QOL). METHODS: The DDD ICD was implanted in 267 patients with drug refractory, symptomatic AF from 45 centers across Europe, the United States, and Canada. Patients completed self-reported, validated QOL assessments at baseline and at 3- and 6-month follow-up visits (The Medical Outcomes Short Form 36 [SF-36] and the Symptom Checklist [SCL]). RESULTS: The mean age of the study group was 62 +/- 12 years, and 73% of the patients were male. A total of 150 patients completed SF-36 assessments, and 138 patients completed SCL assessments at all 3 times. Baseline scores were more impaired (P <.05) on most SF-36 scales compared with norms for a general population, but were similar to a comparison group of patients with AF who were referred to tertiary care centers. The role-physical, physical functioning, vitality, mental health, and social functioning scales all improved significantly with time (all P <.04). Similarly, symptom frequency and severity (SCL) also improved significantly from baseline to 6 months (both P <.01). Shock therapy was delivered in 86 of the 150 patients (57%) with complete SF-36 evaluations. There was no evidence that receiving shocks decreased the relative improvement in QOL associated with implantation of the device. CONCLUSIONS: In a 6-month period, QOL improves after implantation of a DDD ICD with atrial shock and pacing therapies. These improvements were not attenuated by receipt of shocks.

Atrial Fibrillation↗
PubMed1991

Reduction in defibrillator shocks with an implantable device combining antitachycardia pacing and shock therapy.

Implantable defibrillators reduce the risk of sudden death in patients with malignant ventricular arrhythmias, but significant restriction in quality of life can occur as a result of frequent device activation. To determine if a device that provides both antitachycardia pacing and shock therapy can safely reduce the frequency of shocks after implantation, 46 consecutive patients undergoing initial implantation of a defibrillator were studied. In all patients, the implanted device provided antitachycardia pacing and shock therapy. Detected tachycardia characteristics and the results of therapy were stored in the device's memory. There were 42 men and 4 women, aged 26 to 71 years (mean 58.7 +/- 13.5). Left ventricular ejection fraction ranged from 13% to 67% (mean 32.2 +/- 13.4%) and 31 patients had experienced one or more episodes of cardiac arrest. Induced arrhythmias included sustained monomorphic ventricular tachycardia in 38 patients, nonsustained polymorphic ventricular tachycardia in 2 and ventricular fibrillation in 4. Over a total follow-up period of 255 patient-months (range 1 to 13, mean 6.1), 25 patients experienced spontaneous arrhythmic events. In 22 patients, 909 episodes of tachycardia were treated by antitachycardia pacing, which was successful on 840 occasions (92.4%). Acceleration of ventricular tachycardia by pacing therapy was estimated to have occurred 39 times. Syncope occurred once during pacing-induced acceleration of ventricular tachycardia. Forty-four episodes of tachycardia in seven patients were treated directly by shocks because of short tachycardia cycle length; 88% of all detected tachycardias were treated without the need for shocks. Four patients died from cardiorespiratory failure and one patient died suddenly without any detected tachyarrhythmia.(ABSTRACT TRUNCATED AT 250 WORDS)

Anti-Arrhythmia Agents↗